Bubble Baby Families Denied ‘Compassionate Use’ of Live-Saving Therapy
By David Jensen,
Substack
| 05. 25. 2021
Update 5/28: Orchard Exits Life-Saving Bubble-Baby Research in Wake of Flap Over Patient Access
A gene therapy company backed by millions of dollars from the state of California has withheld “compassionate use” of a life-saving therapy sought by parents of children suffering from what is known as the bubble baby disease, according to a patient advocate group and parents.
The families sounded an “SOS” this spring in a letter to the company, Orchard Therapeutics PLC.
“We implore you to treat this as a desperate call for help to save young lives,” the letter said. More than 20 young children are in “urgent need of gene therapy for ADA-SCID (the medical term for the bubble baby disease),” the letter said. (See text here.)
Disclosure of the rejection of the compassionate use treatment is a new twist in the story about the gene therapy, which has saved some 50 lives during its experimental development for bubble babies. The news is likely to intensify criticism of the company for its financially driven decisions concerning the bubble baby disease.
The rare affliction is...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
